Patent AU-2013201495-B2 (AU)
Title: Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus
Inventor: SMITH GALE
IPC: C12N15/00
Filed: 2012-09-27
Granted: 2015-12-03
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2013/049342 Al 4 April 2013 (04.04.2013) W I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/155 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/057546 DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 27 September 2012 (27.09.2012) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/542,040 30 September 2011 (30.09.2011) US 61/542,721 3 October 2011 (03.10.2011) US (84) Designated States (unless otherwise indicated, for every 61/611,834 16 March 2012 (16.03.2012) US kind of regional protection available): ARIPO (BW, GH, 61/614,286 22 March 2012 (22.03.2012) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant (for all designated States except US): TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, NOVAVAX, INC. [US/US]; 9920 Belward Campus Drive, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Rockville, Maryland 20850 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (72) Inventors; and TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicants (for US only): SMITH, Gale [US/US]; c/o ML, MR, NE, SN, TD, TG). NOVAVAX INC., 9920 Belward Campus Drive, Rock- Published: ville, Maryland 20850 (US). WU, Yingyun [CN/US]; c/o -a NOVAVAX INC., 9920 Belward Campus Drive, Rock- with international search report (Art. 21(3) ville, Maryland 20850 (US). MASSARE, Michael - before the expiration of the time limit for amending the [US/US]; c/o NOVAVAX INC., 9920 Belward Campus claims and to be republished in the event of receipt of Drive, Rockville, Maryland 20850 (US). LIU, Ye amendments (Rule 48.2(h)) [CN/US]; c/o NOVAVAX INC., 9920 Belward Campus - with sequence listing part of description (Rule 5.2(a)) Drive, Rockville, Maryland 20850 (US). (74) Agents: TUSCAN, Michael S. et al.; Cooley LLP, 777 6th Street, N.W., Suite 1100, Washington, District of Columbia 20001 (US). (54) Title: RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS Figure 1 r sijo , bl (M RSV FU4h R SVFOC A AR ELP .L&KK(KfR FL G 2" 1* (57) Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of f4 RSV infection. In one aspect, the invention provides recombinant RSV F proteins comprising modified or mutated amino acid se quences as compared to wild-type RSV F proteins. In general, these modifications or mutations increase the expression, reduce the cellular toxicity, and/or enhance the immunogenic properties of the RSV F proteins as compared to wild-type RSV F proteins. In certain exemplary embodiments, the RSV F proteins are human RSV F proteins.